Royal Bank of Canada »

Cartesian Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Cartesian Therapeutics (RNAC) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Cartesian Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Cartesian Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cartesian Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2024-09-30 $52k 2.9k 17.54
2024-06-30 $77k 2.8k 27.19

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core S&p500 Etf (IVV)
Bk Nova Cad (BNS)
Ishares Tr Russell 2000 Etf (IWM)
Bank Of Montreal Cadcom (BMO)
JPMorgan Chase & Co. (JPM)
Enbridge (ENB)
Cibc Cad (CM)

View all positions for Royal Bank of Canada

Top funds holding Cartesian Therapeutics

Siren
BlackRock
BlackRock
Citadel Advisors
Jpmorgan Chase & Co
MPM Oncology Impact Management
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Erste Asset Management GmbH
State Street Corporation
Geode Capital Management
Yale University
Logos Global Management
683 Capital Management
Northern Trust

View all funds holding Cartesian Therapeutics